• 2022年度
• 2021年度
• 2020年度
• 2019年度
• 2018年度
• 2017年度
• 2016年度
• 2015年度
• 2014年度
• 2013年度

2016年度論文業績

• Tamai H, Yamaguchi H, Miyake K, Takatori M, Kitano T, Yamanaka S, Yui S, Fukunaga K, Nakayama K, Inokuchi K. Amlexanox downregulates S100A6 to sensitize KMT2A/AFF1-positive acute lymphoblastic leukemia to TNF-α treatment. Cancer Res, in press.
• Omori I, Yamaguchi H, Miyake K, Miyake N, Kitano T, Inokuchi K. D816V mutation in the KIT gene activation loop has a greater cell proliferative and anti-apoptotic ability than N822K mutation in core binding factor-acute myeloid leukemia. Exp Hematol. In press.
• Yamato G, Yamaguchi H, Handa H, Shiba N, Kawamura M, Wakita S, Inokuchi K, Hara Y, Ohki K, Okubo J, Park M, Sotomatsu M, Arakawa H, Hayashi Y. Clinical Features and Prognostic Impact of PRDM16 Expression in Adult Acute Myeloid Leukemia. Genes, Chromosomes and Cancer. In press.
• Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, Takahashi S, Uchida N, Onishi Y, Ohashi K, Ozawa Y, Kanamori H, Yamaguchi H, Fukuda T, Ichinohe T, Takanashi M, Atsuta Y, Teshima T.　 Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant. In press.
• Muramatsu H, Okuno Y, Yoshida K, Shiraishi Y, Doisaki S, Narita A, Sakaguchi H, Kawashima N, Wang X, Xu Y, Chiba K, Tanaka H, Hama A, Sanada M, Takahashi Y, Kanno H, Yamaguchi H, Ohga S, Manabe A, Harigae H, Kunishima S, Ishii E, Kobayashi M, Koike K, Watanabe K, Ito E, Takata M, Yabe M, Ogawa S, Miyano S, Kojima S. Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes. Genetics in Medicine. In press.
• Ryotokuji T, Yamaguchi H, Ueki T, Usuki K, Kurosawa S, Kobayashi Y, Kawata E, Tajika K, Gomi S, Kanda J, Kobayashi A, Omori I, Marumo A, Fujiwara Y, Yui S, Terada K, Fukunaga K, Hirakawa T, Arai K, Kitano T, Kosaka F, Tamai H, Nakayama K, Wakita S, Fukuda T, Inokuchi K. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations Haemtologica. 2016 Sep;101(9):1074-81.
• Fujiwara Y, Yamaguchi H, Kobayashi K, Yamanaka S, Yui S, Fukunaga K, Ryotokuji T, Hirakawa T, Okabe M, Wakita S, Tamai H, Okamaoto M, Nakayama K, Takeda S, Inokuchi K. Mechanical ventilation produces better outcomes in an intensive care unit than in a sterile ward in hematological malignancy patients with respiratory failure. Int Med. 2016;55(12):1537-45.
• Inokuchi K, Okamoto M, Nakayama K, Tamai H, Yamaguchi H. Late-onset Imatinib-induced Liver Failure Treated with Dasatinib for Two Years Resulted in Long-term Undetectable Response. Case Report: J Leuk 2016, 4: 220
• Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Wakita S, Kanamori H, Usuki K, Uoshima N, Yanada M, Shono K, Ueki T, Mizuno I, Yano S, Takeuchi J, Kanda J, Okamura H, Inamoto Y, Inokuchi K, Fukuda T. Decision analysis of post-remission therapy in cytogenetically intermediate-risk acute myeloid leukemia: The impact of FLT3-ITD, NPM1, and CEBPA gene mutations. Biology of Blood and Marrow Transplant. 2016 Jun;22(6):1125-32.
• Tamai H, Yamaguchi H, Miyake K, Takatori M, Kitano T, Dan K, Inokuchi K. Sensitivity of RCSD1–ABL1 Positive Acute Lymphoblastic Leukemia to TKIs Varies between Fusion sites in Ph-like Acute Lymphoblastic Leukemia. International Journal of Recent scientific Research, 2016, 7:9729-9733.
• Moriya K, Niizuma H, Rikiishi T, Yamaguchi H, Sasahara Y, Kure S. Hoyeraal-Hreidarsson syndrome in a patient with novel compound heterozygous RTEL1 gene mutations. Pediatric Blood &Cancer. 2016 Sep;63(9):1683-4.
• Ozaki S, Funasaka Y, Shimizu A, Kawarasaki M, Kanazaki A, Futagami A, Yamaguchi H, Sugisaki Y, Saeki H. Follicular lymphoma presenting follicular papules in the skin: a case report. Journal of Dermatology. J Dermatol. 2017 Jan;44(1):111-113.
• Imai Y, Ohta E, Takeda S, Sunamura S, Ishibashi M, Tamura H, Wang YH, Deguchi A, Tanaka J, Maru Y, Motoji T. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI Insight. 2016;1(5):e85061.
• Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Ann Hematol. 2016;95(9):1465-72.
• Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, Moriya K, Choi I, Tamada K, Inokuchi K. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016 Sep 2;4(9):779-88.
• Moriya K, Tamura H, Nakamura K, Hosone M, Inokuchi K. A primary esophageal MALT lymphoma patient with Helicobacter pylori infection achieved complete remission after H. pylori eradication without anti-lymphoma treatment. Leuk Res Rep. 2016;7:2-5.